Expiration Date: February 28, 2017
Media: Internet - based
This activity is designed to update physicians on data that has been recently presented in Singapore so that participants can assess and apply findings to their clinical practices in managing patients with non-small cell lung cancer. Some key trial information was presented at this conference on the use of checkpoint inhibitors alone or in combination to manage advanced forms of these tumors. Additionally, a number of important data sets were also released concerning the use of targeted agents in EGFR-mutated and ALK-rearranged NSCLC.
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical oncologists and fellows who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.
At the conclusion of this activity, you should be better prepared to:
- Summarize emerging clinical trial data concerning novel compounds and strategies for patients with advanced NSCLC
- Discuss evolving evidence concerning the role of biomarkers in the management of lung cancer
- Explain recent clinical trial results in the context of applying them to clinical practice in the management of advanced forms of lung cancer
Faculty, Staff, and Planners' Disclosures
Edward Garon, MD
Hematology & Oncology
Ronald Reagan UCLA Medical Center
UCLA Medical Center
Santa Monica, CA
Disclosure: Grant/Research Support: AstraZeneca, BMS, Genentech, Lilly, Merck, Pfizer, Novartis.
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief, Medical Oncology
Associate Director, Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT
Disclosure: Scientific Advisory Boards: Biothera, Diatech, Kolltan, N to 1. Consultant: Lilly, Genentech/Roche, Gilead, Merck, Pfizer. Grant/Clinical Trial Support: Genentech.
The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise